((自动化翻译由路透提供，请见免责声明 ))
9月27日 - ** 经纪公司Leerink称，Agios制药公司的 实验性药物mitapivat可能与辉瑞公司的 镰状细胞病治疗药物Oxbryta具有类似的生理效应。
** 周三，辉瑞公司从所有获批市场上撤回了 (link) Oxbryta，理由是该药有可能引发痛苦的并发症和死亡。
** Leerink分析师安德鲁-贝伦斯（Andrew Berens）说，如果正在进行的mitapivat晚期试验取得成功，撤出Oxbryta对Agios来说可能是一个机会。
** 然而，Berens表示，与辉瑞的药物结果类似的风险可能仍然是Agios股价的一个悬念。
** 辉瑞公司称，Oxbryta 的试验数据显示血管闭塞性危象（一种血流受阻的并发症）出现了失衡。
** 8家券商中有5家将Agios评为 "买入 "或更高评级，3家为 "持有"；其PT中值为56美元--LSEG数据
** 股价今年以来上涨了一倍多
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.